A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

K. Yamazaki, H. Yasui, K. Yamaguchi, Y. Kagawa, Y. Kuboki, T. Yoshino, M. Gamoh, Y. Komatsu, H. Satake, M. Goto, H. Tanioka, E. Oki, M. Kotaka, A. Makiyama, T. Denda, J. Soeda, K. Shibya, M. Iwata, K. Oba, T. Kato

Research output: Contribution to journalArticle

74 Citations (Scopus)
Original languageEnglish
Pages (from-to)v71
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - Jun 1 2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Yamazaki, K., Yasui, H., Yamaguchi, K., Kagawa, Y., Kuboki, Y., Yoshino, T., Gamoh, M., Komatsu, Y., Satake, H., Goto, M., Tanioka, H., Oki, E., Kotaka, M., Makiyama, A., Denda, T., Soeda, J., Shibya, K., Iwata, M., Oba, K., & Kato, T. (2018). A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v71. https://doi.org/10.1093/annonc/mdy151.252